Back to Journals » Clinical Ophthalmology » Volume 6

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma

Authors Mizoguchi T, Ozaki M, Unoki, Dake, Eto, Arai

Received 29 April 2012

Accepted for publication 5 July 2012

Published 25 September 2012 Volume 2012:6 Pages 1579—1584


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Takanori Mizoguchi,1 Mineo Ozaki,2 Kazuhiko Unoki,3 Yoshinori Dake,4 Takahiko Eto,5 Miki Arai6

Mizoguchi Eye Clinic, 2Ozaki Eye Clinic, Miyazaki, Japan; 3Unoki Eye Clinic, Kagoshima, Japan; 4Dake Eye Clinic, Nagasaki, Japan; 5Eto Eye Clinic, Oita, Japan; 6Arai Eye Clinic, Fukuoka, Japan

Purpose: We compared the intraocular pressure (IOP)-lowering effect of tafluprost 0.0015% once daily with travoprost 0.004% once daily in Japanese patients with normal-tension glaucoma (NTG).
Methods: One hundred sixteen patients with NTG were randomized to use tafluprost 0.0015% or travoprost 0.004% once daily for 12 weeks, followed by a washout period of 4 weeks between switching medications. IOP was measured at baseline and 4, 8, and 12 weeks of each treatment period.
Results: Ninety patients completed both treatment periods and had IOP data available for evaluation. In both groups, a significant decrease in IOP was observed for all measurement points compared with baseline values (P < 0.0001). There was no significant difference in IOP at each time point between the two groups. Both drugs were effective (defined as more than 10% IOP reduction) in 39 (43%) of 90 patients; only tafluprost was effective in 26 (29%) patients, and only travoprost was effective in 17 (19%) patients. Eight (9%) patients were nonresponders to both drugs.
Conclusions: Tafluprost and travoprost were equally effective in lowering IOP in patients with normal-tension glaucoma. However, patients with normal-tension glaucoma may vary in response to each medication.

Keywords: intraocular pressure reduction, normal-tension glaucoma, responder, tafluprost 0.005%, travoprost 0.004%

Corrigendum for this paper has been published

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.